STAREE
2026
STAtin Therapy for Reducing Events in the Elderly
In 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg improved one of two co-primary outcomes disability-free survival and major cardiovascular events compared with placebo.
Resultado
Eficacia: Co-primary: (1) disability-free survival, defined as survival free of dementia and persistent physical disability; (2) major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke; registry definition also lists coronary revascularisation)HR 0,70 (IC del 95% 0,61-0,82) · P < 0,001
Por debajo de 1 a favor de atorvastatin 40 mg, por encima de 1 a favor de placebo.
- Diferencia absoluta
- 2,3 puntos
- NNT
- 44
La diferencia absoluta y el NNT se derivan de las tasas de eventos.
También se informa: The other co-primary, disability-free survival, was unchanged: 12.8% vs 13.6% (HR 0.94, 95% CI 0.84-1.05; P = 0.25). Muscle, liver and diabetes-related adverse events were more common with atorvastatin; serious adverse events 2.7% in both arms.
- Subtema
- Primary prevention
- Diseño
- Double-blind, placebo-controlled RCT, 1:1, recruited through Australian general practice, average follow-up about 6 years planned, time-to-first-event analyses for each co-primary endpoint
- Relevancia
- Define la práctica: un ensayo imprescindible en la especialidad.
- Fuente
- Zoungas S, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607314
Discusión y crítica
The trial general practice has been waiting for: a statin started after 70, in people without cardiovascular disease, diabetes or dementia. Cardiovascular events fall by 30% relative and 2.3 percentage points absolute over six years, roughly 43 people treated for one event avoided. The endpoint older patients are usually promised, years free of dementia and disability, did not move, and the entrants were healthy volunteers rather than the frail, comorbid 80-year-olds in whom the question is hardest.